In a population of RA patients with active disease following treatment escalation, minimal clinically important improvements with specificity equal to 0.80 were equal to −1.02 (CI: −1.44–−0.83) for DAS28-CRP and −13.1 (CI: −17.5–−10.7) for SDAI [54]. The gene discussed is CRP; the disease is rheumatoid arthritis.